Radiopharm Theranostics (RDPTF) Current Assets (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Current Assets for 3 consecutive years, with $155530.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 39.06% year-over-year to $155530.7 in Q2 2026; TTM through Jun 2026 was $155530.7, a 39.06% decrease from a year earlier, with the FY2026 full-year figure at $148910.5, down 99.63% from the prior year.
• Current Assets was $155530.7 for Q2 2026 at Radiopharm Theranostics, down from $255238.2 in the prior quarter.
• Over five years, Current Assets peaked at $44.4 million in Q4 2024 and troughed at $150575.6 in Q2 2024.
• A 3-year average of $11.2 million and a median of $205384.4 in 2026 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 69.51% in 2025 and plunged 39.06% in 2026, its largest moves.
• Over 3 years, Current Assets stood at $44.4 million in 2024, then tumbled by 99.42% to $255238.2 in 2025, then sank by 39.06% to $155530.7 in 2026.
• The last three Current Assets figures came in at $155530.7 (Q2 2026), $255238.2 (Q2 2025), and $44.4 million (Q4 2024), per Business Quant data.